Fluorescence In Situ Hibridization (FISH)

What Is FISH?

FISH (fluorescence in situ hibridization) is a cytogenetic technique developed by biomedical researchers in the early 1980s that is used to detect and localize the presence or absence of specific DNA sequences on chromosomes. FISH uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence complementarity.

FISH Probes / Panels by Disease Application

 

FISH Panels
Panel Probes Validated for use in Paraffin
AML Panel AML1/ETO, PML/RARA, CBFB, MLL, D7S522,D8Z2
B-Cell Lymphoma Panel BCL6, MALT, BCL1 (CCND1), IGH/BCL2
x
Burkitt’s Lymphoma Panel MYC/IGH
x
Double/Triple Hit Lymphoma MYC, MYC/IGH, IGH/BCL2, BCL6
x
CML Panel BCR/ABL + ASS
CLL Panel D13S319/13q34, D12Z3, ATM, TP53
Standard ALL Panel MLL, TEL/AML1 (ETV6/RUNX1), BCR/ABL1, p16/CEP9, IGH/MYC/CEP8
MDS Panel EGR1/5p15, D7S522/CEP7, D20S108/D8Z2, TP53/D17Z1
*MM/MGUS Panel TP53/D17Z1, FGFR3/IGH, D13S319/13q34, MLL, CDKN2C/CKC1B(1p/1q)
reflexive probes for IGH gain IGH/CCND1, IGH/MAF, IGH/CCND3, IGH/MAFB
MPN/Hypereosinophilia/Eosinophilia FIP1L1/CHIC2/PDGFRA, PDGFRB, FGFR1
ALL Panel Pediatric Add On Cen4/Cen10/Cen17, TCF3/PBX1

*Plasma cell enrichment performed on all MM/MGUS specimens

Single FISH Probes
Gene Rearrangement Translocation Probes  Location Disease Purpose Validated for use in Paraffin
MYB/D6Z1 6q23.3 Lymphoma, Myeloma, Waldenstrom’s
AML1/ETO (RUNX1/RUNX1T1) t(8;21) AML M2
ATM 11q22.3 CLL
BCL6 3q27 DLBCL
x
BCL2 18q21 Follicular or DLBCL
BCL2/IGH t(14;18) Follicular or DLBCL
x
BCR/ABL1 + ASS t(9;22) CML, AML or ALL
CBFB/MYH11 inv(16q22) AMLM2/M4
CCND1/IGH(BCL1/IGH) t(11;14) Mantle Cell Lymphoma, Myeloma
x
CCND3/IGH t(6;14) Multiple Myeloma
CDKN2C/CKS1B 1p32.3/1q21 Multiple Myeloma
D13S25/D13S319 13q14 CLL, MM, MPD deletion
D20S108 20q12 Myeloid Disorders Del 20q
D7S796/D7S543 7q22/7q31 Myeloid Disorders Del 7q/monosomy 7
DEK/NUP214 (CAN) t(6;9) AML
FIP1L1/CHIC2/PDGFRA 4q12 deletion Hypereosinophilia
EGR1/5p15.31 5q31/5p15.31 Myeloid disorders deletion 5q/monosomy 5
EVI1 t(3q26) Myeloid Leukemia
ETV6/RUNX1 (TEL/AML1) t(12;21) (cryptic) Pediatric precursor B-ALL
FGFR3/IGH t(4:14) Multiple Myeloma
IGH break-apart IGH gene rearrangement Lymphoma, MM, HCL
x
MAF/IGH t(14;16) Multiple Myeloma
MAFB/IGH t(14;20) Multiple Myeloma
MALT1 t(11;18) or variant MALT Lymphoma
x
MLL MLL gene rearrangement rearrangement or amplification
MLL/MLLT3 t(9;11) AML
MYC break apart 8q24 rearrangement
MYC/IGH t(8;14) Burkitt’s lymphoma
x
NUP98 11p15 AML
PDGFRB 5q33 Myeloproliferative disease
PML/RARA t(15;17) AML M3
RB1 13q14 Retinoblastoma deletion
TCF3/PBX1 t(1;19) Pediatric ALL
TCRAD 14q11 T-ALL
TP53 17p13 Solid tumors, lymphoid or myeloid leukemias, MM
TP16/D9Z3 9p21/Cen 9 T-cell lymphoblastic leukemia, pediatric ALL
D12Z3 12q10 CLL
ATM 11q22.3 CLL
CEP 4 4q10 Pediatric precursor B-ALL
CEP 10 10q10 Pediatric precursor B-ALL
CEP 17 17q10 Pediatric precursor B-ALL
CEP9 9q10 lymphoid or myeloid leukemia, MDS
CEP8 8q10 Myeloid leukemia or MDS
CEP7 7q10 Myeloid or lymphoid leukemia, NHL
CEP X and Y Xq10, Yq10 engraftment

This is a unique website which will require a more modern browser to work!

Please upgrade today!